Literature DB >> 26415102

Systematic transcriptome analysis reveals elevated expression of alcohol-metabolizing genes in NAFLD livers.

Ruixin Zhu1, Susan S Baker2, Cynthia A Moylan3,4, Manal F Abdelmalek3, Cynthia D Guy5, Fausto Zamboni6, Dingfeng Wu1, Weili Lin1, Wensheng Liu2, Robert D Baker2, Sugantha Govindarajan7, Zhiwei Cao1, Patrizia Farci8, Anna Mae Diehl3, Lixin Zhu2.   

Abstract

Obese animals and non-alcoholic fatty liver disease (NAFLD) patients exhibit elevated blood alcohol, suggesting potential contributions of alcohol metabolism to the development of NAFLD. Liver gene expression in patients with biopsy-proven mild (N = 40) and severe (N = 32) NAFLD were compared to that in healthy liver donors (N = 7) and alcoholic hepatitis (AH; N = 15) using microarrays. Principal components analyses (PCA) revealed similar gene expression patterns between mild and severe NAFLD which clustered with those of AH but were distinct from those of healthy livers. Differential gene expression between NAFLD and healthy livers was consistent with established NAFLD-associated genes and NAFLD pathophysiology. Alcohol-metabolizing enzymes including ADH, ALDH, CYP2E1, and CAT were up-regulated in NAFLD livers. The expression level of alcohol-metabolizing genes in severe NAFLD was similar to that in AH. The NAFLD gene expression profiles provide new directions for future investigations to identify disease markers and targets for prevention and treatment, as well as to foster our understanding of NAFLD pathogenesis and pathophysiology. Particularly, increased expression of alcohol-metabolizing genes in NAFLD livers supports a role for endogenous alcohol metabolism in NAFLD pathology and provides further support for gut microbiome therapy in NAFLD management.
Copyright © 2015 Pathological Society of Great Britain and Ireland. Published by John Wiley © Sons, Ltd. Copyright © 2015 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  ADH; ALDH; CYP2E1; non-alcoholic

Mesh:

Substances:

Year:  2016        PMID: 26415102     DOI: 10.1002/path.4650

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  17 in total

1.  Adaptation of Oxidative Phosphorylation Machinery Compensates for Hepatic Lipotoxicity in Early Stages of MAFLD.

Authors:  Pia Fahlbusch; Aleksandra Nikolic; Sonja Hartwig; Sylvia Jacob; Ulrike Kettel; Cornelia Köllmer; Hadi Al-Hasani; Stefan Lehr; Dirk Müller-Wieland; Birgit Knebel; Jörg Kotzka
Journal:  Int J Mol Sci       Date:  2022-06-20       Impact factor: 6.208

2.  Dietary copper-fructose interactions alter gut microbial activity in male rats.

Authors:  Ming Song; Xiaohong Li; Xiang Zhang; Hongxue Shi; Miriam B Vos; Xiaoli Wei; Yuhua Wang; Hong Gao; Eric C Rouchka; Xinmin Yin; Zhanxiang Zhou; Russell A Prough; Matthew C Cave; Craig J McClain
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-10-12       Impact factor: 4.052

3.  Induction of CYP2E1 in non-alcoholic fatty liver diseases.

Authors:  Ghanim Aljomah; Susan S Baker; Wensheng Liu; Rafal Kozielski; Janet Oluwole; Benita Lupu; Robert D Baker; Lixin Zhu
Journal:  Exp Mol Pathol       Date:  2015-11-10       Impact factor: 3.362

Review 4.  Alcohol and Hepatocellular Carcinoma: Adding Fuel to the Flame.

Authors:  Pierluigi Ramadori; Francisco Javier Cubero; Christian Liedtke; Christian Trautwein; Yulia A Nevzorova
Journal:  Cancers (Basel)       Date:  2017-09-25       Impact factor: 6.639

Review 5.  Alternative RNA Splicing in the Pathogenesis of Liver Disease.

Authors:  Nicholas J G Webster
Journal:  Front Endocrinol (Lausanne)       Date:  2017-06-21       Impact factor: 5.555

6.  Lingguizhugan Decoction Protects against High-Fat-Diet-Induced Nonalcoholic Fatty Liver Disease by Alleviating Oxidative Stress and Activating Cholesterol Secretion.

Authors:  Lili Yang; Weili Lin; Colleen A Nugent; Shijun Hao; Haiyan Song; Tao Liu; Peiyong Zheng
Journal:  Int J Genomics       Date:  2017-12-31       Impact factor: 2.326

7.  Comparison of transcriptome responses to glyphosate, isoxaflutole, quizalofop-p-ethyl and mesotrione in the HepaRG cell line.

Authors:  Robin Mesnage; Martina Biserni; Eva Wozniak; Theodoros Xenakis; Charles A Mein; Michael N Antoniou
Journal:  Toxicol Rep       Date:  2018-08-11

8.  CCL20 is up-regulated in non-alcoholic fatty liver disease fibrosis and is produced by hepatic stellate cells in response to fatty acid loading.

Authors:  Xin Chu; Qunyan Jin; Hui Chen; G Craig Wood; Anthony Petrick; William Strodel; Jon Gabrielsen; Peter Benotti; Tooraj Mirshahi; David J Carey; Christopher D Still; Johanna K DiStefano; Glenn S Gerhard
Journal:  J Transl Med       Date:  2018-04-24       Impact factor: 5.531

Review 9.  A Role for Gut Microbiome Fermentative Pathways in Fatty Liver Disease Progression.

Authors:  Paula Iruzubieta; Juan M Medina; Raúl Fernández-López; Javier Crespo; Fernando de la Cruz
Journal:  J Clin Med       Date:  2020-05-07       Impact factor: 4.241

10.  An exploratory study examining how nano-liquid chromatography-mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease.

Authors:  Zobair M Younossi; Azza Karrar; Mariaelena Pierobon; Aybike Birerdinc; Maria Stepanova; Dinan Abdelatif; Zahra Younoszai; Thomas Jeffers; Sean Felix; Kianoush Jeiran; Alex Hodge; Weidong Zhou; Fanny Monge; Lakshmi Alaparthi; Vikas Chandhoke; Zachary D Goodman; Emanuel F Petricoin
Journal:  BMC Med       Date:  2018-09-12       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.